Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin for Glucose Transporter Type I Deficiency
NCT02021526Phase 2Withdrawn
- Start
- Dec 2015
- Primary completion
- Jun 2020
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of triheptanoin in Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS) (2 arms). Primary endpoints: Change in risk for Metabolic Syndrome at 9 months, Change on Biomarkers at 9 months and 1 more. Planned start Dec 2015; status: withdrawn.
02
Drugs
triheptanoin
03
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS)
Beyond the preview
Go deeper on NCT02021526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021526.